Does the opioid-sparing effect of NSAIDs benefit the patient in the postoperative period?

Alexander Ng, MBChB, MD, FRCA, Justiaan Swanevelder, MBChB, MMed(Anaes), FCA(SA), FRCA

Abstract


-

Keywords


-

Full Text:

PDF

References


Ng A, Parker J, Toogood L, et al.: Does the opioid-sparing effect of rectal diclofenac following total abdominal hysterectomy benefit the patient? Br J Anaesth. 2002; 88: 714-716.

Tarkkila P, Saarnivaara L: Ketoprofen, diclofenac or ketorolac for pain after tonsillectomy in adults? Br J Anaesth. 1999; 82: 56-80.

McCrory CR, Lindahl SGE: Cyclooxygenase inhibition for postoperative analgesia. Anesth Analg. 2002; 95: 169-176.

Barden J, Edwards J, Moore RA, et al.: Single dose oral diclofenac for postoperative pain. Cochrane Database Syst Rev. 2004; (2): CD004768.

Edwards JE, Loke YK, Moore RA, et al.: Single dose piroxicam for acute postoperative pain. Cochrane Database Syst Rev. 2000; (4): CD002762.

Buvanendran A, Kroin JS, Tuman KJ, et al.: Effects of perioperative administration of a selective cyclooxygenase 2 inhibitor on pain management and recovery of function after knee replacement. JAMA. 2003; 290: 2411-2418.

Moiniche S, Romsing JMS, Dahl JB, et al.: Nonsteroidal antiinflammatory drugs and the risk of operative site bleeding after tonsillectomy: A quantitive systematic review. Anesth Analg. 2003; 96: 68-77.

Smith LA, Carroll D, Edwards JE, et al.: Single-dose ketorolac and pethidine in acute postoperative pain: Systematic review with meta-analysis. Br J Anaesth. 2000; 84: 48-58.

Jorgensen H, Wetterslev J, Moiniche S, et al.: Epidural local anaesthetics versus opioid-based analgesic regimens for postoperative gastrointestinal paralysis, PONV and pain after abdominal surgery. Cochrane Database Syst Rev. 2000; CD001893.

Ng A, Smith G: Gastroesophageal reflux and aspiration in anesthetic practice. Anesth Analg. 2001; 93: 494-513.

Lee A, Done M: The use of nonpharmacologic techniques to prevent postoperative nausea and vomiting: A meta-analysis. Anesth Analg. 1999; 88: 1362-1369.

Silverstein FE, Faich G, Goldstein JL, et al.: Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis. The Class Study; A randomized controlled trial. JAMA. 2000; 284: 1247-1255.

Forrest JB, Camu F, Greer IA, et al.: Ketorolac, diclofenac and ketoprofen are equally safe for pain relief after major surgery. Br J Anaesth. 2002; 88: 227-233.

Ng A, Smith G, Davidson AC: Analgesic effects of parecoxib following total abdominal hysterectomy. Br J Anaesth. 2003; 90: 746-749.

Warltier DC, Marret E, Flahault A, et al.: Effects of postoperative, nonsteroidal, anti-inflammatory drugs on bleeding risk after tonsillectomy. Meta-analysis of randomized controlled trials. Anesthesiology. 2003; 98: 1497-1502.

Joshi W, Connelly NR, Reuben SS, et al.: An evaluation of the safety and efficacy of administering rofecoxib for postoperative pain management. Anesth Analg. 2003; 97: 35-38.

Brown KM, Saunders MM, Kirsch T, et al.: Effect of COX-2 specific inhibition on fracture-healing in the rat femur. J Bone Joint Surg. 2004; 86: 116-123.

Bombardier C, Laine L, Reicin A, et al.: Vigor study group. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. N Engl J Med. 2000; 343: 1520-1528.

Ray WA, Stein M, Daugherty JR, et al.: COX-2 selective nonsteroidal anti-inflammatory drugs and risk of serious coronary heart disease. Lancet. 2002; 360: 1071-1073.

Juni P, Nartey L, Reichenbach S, et al.: Risk of cardiovascular events and rofecoxib: Cumulative meta-analysis. Lancet. 2004; 364: 2021-2029.

Bresalier RS, Sandler RS, Quan H, et al.: Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med. 2005; 352: 1092-1102.

Dieppe PA: Lessons from the withdrawal of rofecoxib. BMJ. 2004; 329: 867-868.

Kimmel SE, Berlin JA, Reilly M, et al.: Patients exposed to rofecoxib and celecoxib have different odds of nonfatal myocardial infarction. Ann Intern Med. 2005; 142: 157-164.

Graham DJ, Campen D, Hui R, et al.: Risk of acute myocardial infarction and sudden cardiac death in patients treated with cyclo-oxygenase 2 selective and non-selective anti-inflammatory drugs: Nested case-control study. Lancet. 2005; 365: 475-482.

Solomon DH, Schneeweiss S, Glynn RJ, et al.: Relationship between selective cyclooxygenase-2 inhibitors and acute myocardial infarction in older adults. Circulation. 2004; 109: 2068-2073.

National Institutes of Health: NIH halts use of COX-2 inhibitor in large cancer prevention trial. Available at http://www.nih.gov/news/pr/dec2004/od-17.htm. Accessed March 31, 2005.

Gottlieb S: Warnings issued over COX-2 inhibitors in US and UK. BMJ. 2005; 330: 9.

Solomon SD, McMurray JJV, Pfeffer MA, et al.: Cardio -vascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med. 2005; 352: 1071-1080.

Nussmeier NA, Whelton AA, Brown MT, et al.: Complications of the COX-2 inhibitors parecoxib and valdecoxib after cardiac surgery. N Engl J Med. 2005; 352: 1081-1091.

Ott E, Nussmeier NA, Duke PC, et al.: Efficacy and safety of the cyclooxygenase 2 inhibitors parecoxib and valdecoxib in patients undergoing coronary artery bypass surgery. J Thorac Cardiovasc Surg. 2003; 125: 1481-1492.

National Institutes of Health: Use of non-steroidal antiinflammatory drugs suspended in large Alzheimer’s disease prevention trial. Available at: http://www.nih.gov/news/pr/dec2004/od-20.htm. Accessed March 31, 2005.

Lloyd K: Important new safety information cardiovascular risk, celecoxib, valdecoxib, parecoxib. Pfizer, Inc.: 2005.

Ray WA, Griffin MR, Stein CM: Cardiovascular toxicity of valdecoxib. N Engl J Med. 2004; 351: 2767.




DOI: https://doi.org/10.5055/jom.2005.0017

Refbacks

  • There are currently no refbacks.